Achillion Pharmaceuticals competitors

As part of the executive team, responsible for building a sustainable profitable business unit for Merck in the new rapidly growing biosimilar space and to become a recognized and respected global player. Accountable for: building and leading a high performance global talented team; developing new ideas for commercialization; nurturing a 'start up’ entrepreneurial environment and a 'different than Rx' mindset; delivering on strategic and financial goals for the unit; and most importantly playing a significant role in driving a step change in the healthcare paradigm by driving greater affordability and access to important quality biologics for patients around the world.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Ronald Piervincenzi is a Chief Executive Officer at United States Pharmacopeia and is based in Rockville, Maryland. He has worked as Principal at McKinsey & Company and VP Development Sciences Business Strategy at BIOGEN INC.. Ronald studied at Hofstra University between 1989 and 1993 and Duke University between 1993 and 2000.